喜炎平联合奥司他韦治疗流感病毒性肺炎的临床分析  

Clinical Analysis of Xiyanping Combined with Oseltamivir in the Treatment of Influenza Virus Pneumonia

作　　者：钟石古 ZHONG Shigu(Department of Pediatrics,Anyuan County People's Hospital,Anyuan 342100,Jiangxi,China)

机构地区：[1]安远县人民医院儿科,江西安远342100

出　　处：《医学信息》2025年第4期107-111,共5页Journal of Medical Information

摘　　要：目的探讨喜炎平联合奥司他韦治疗流感病毒性肺炎患者的临床效果。方法选取2021年12月-2023年11月安远县人民医院收治的78例流感病毒性肺炎患者为研究对象,按照随机数字表法将其分为对照组和观察组,每组39例。对照组口服奥司他韦治疗,观察组在对照组基础上应用喜炎平注射液静脉滴注给药治疗。比较两组治疗效果、不良反应(精神差、恶心呕吐、腹痛腹泻、皮疹)发生率、临床症状转归时间(发热、乏力、憋喘、气促、湿罗音消失时间及核酸转阴时间)、炎性因子水平[白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、高敏C反应蛋白(hs-CRP)]、肺功能水平[用力肺活量(FVC)、第1秒最大呼气量(FEV1)、最高呼气流速(PEF)、用力呼气25%流速(MEF25)]。结果观察组治疗总有效率为97.44%,高于对照组治疗总有效率的79.49%(P<0.05)。观察组不良反应发生率为10.26%,与对照组的12.82%比较,差异无统计学意义(P>0.05)。观察组发热、乏力、憋喘、气促、湿罗音、核酸转阴等临床症状转归时间均低于对照组(P<0.05)。观察组炎性因子水平低于对照组(P<0.05)。观察组肺功能水平高于对照组(P<0.05)。结论喜炎平联合奥司他韦治疗流感病毒性肺炎患者的临床效果确切,能够快速缓解患者临床症状,减轻炎性因子水平,提高患者肺功能,值得临床应用。Objective To investigate the clinical effect of Xiyanping combined with oseltamivir in the treatment of patients with influenza virus pneumonia.Methods A total of 78 patients with influenza virus pneumonia admitted to Anyuan County People's Hospital from December 2021 to November 2023 were selected as the research objects.According to the random number table method,they were divided into control group and observation group,with 39 patients in each group.The control group was treated with oral oseltamivir,and the observation group was treated with Xiyanping injection intravenous drip on the basis of the control group.The treatment effect,incidence of adverse reactions(poor spirit,nausea and vomiting,abdominal pain and diarrhea,rash),clinical symptom outcome time(fever,fatigue,asthma,shortness of breath,wet rale disappearance time and nucleic acid negative conversion time),inflammatory factor levels[interleukin-1β(IL-1β),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)],lung function levels[forced vital capacity(FVC),the forced expiratory volume in the first second(FEV1),peak expiratory flow(PEF),maximum expiratory flow rate at 25%(MEF25)]were compared between the two groups.Results The total effective rate of treatment in the observation group was 97.44%,which was higher than 79.49%in the control group(P<0.05).The incidence of adverse reactions in the observation group was 10.26%,which was compared with 12.82%in the control group,the difference was not statistically significant(P>0.05).The time of clinical symptoms such as fever,fatigue,suffocation,shortness of breath,wet rales and nucleic acid negative conversion in the observation group were lower than those in the control group(P<0.05).The level of inflammatory factors in the observation group was lower than that in the control group(P<0.05).The level of lung function in the observation group was higher than that in the control group(P<0.05).Conclusion Xiyanping combined with oseltamivir has a definite clinical

关 键 词：喜炎平 奥司他韦 流感病毒性肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]